GlassScriptPhysician profile
Ali Y Salman
NPI 1851570139
$6,479.48
in general payments reported to CMS, 2019-2025
32 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,877 · 2020: $1,436 · 2021: $570 · 2022: $920 · 2023: $469 · 2024: $453 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.08 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,747.81 | 2019 | |
| Boston Scientific Corporation | $1,736.67 | 2020-2023 | Peripheral Rotalink Plus, Jetstream Sc |
| Janssen Pharmaceuticals, INC | $738.97 | 2020-2024 | Xarelto |
| Amgen INC. | $349.54 | 2020-2023 | Repatha |
| Actelion Pharmaceuticals US, INC. | $237.00 | 2024-2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $208.54 | 2021-2025 | |
| Inari Medical, INC. | $146.60 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $129.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $114.95 | 2020-2022 | |
| Philips North America LLC | $93.36 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $89.82 | 2022-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $89.32 | 2021-2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $84.82 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $74.86 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $67.58 | 2024 | Arcalyst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $58.39 | 2020 | |
| Alnylam Pharmaceuticals INC. | $56.27 | 2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $52.51 | 2023-2025 | Verquvo |
| G Medical Diagnostic Services, INC. | $45.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.31 | 2025 | |
| Shockwave Medical, INC | $43.66 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $36.14 | 2022 | |
| Chiesi USA, INC. | $30.24 | 2023-2025 | Kengreal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.46 | 2021 | |
| Novo Nordisk INC | $27.01 | 2025 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $24.72 | 2025 | Inspire |
| Heartflow, INC. | $23.51 | 2025 | |
| Tactile Systems Technology INC | $23.49 | 2025 | Nimbl, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.04 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $19.80 | 2025 | |
| Bardy Diagnostics, INC. | $19.35 | 2022 | |
| Kestra Medical Technology Services, INC. | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Salman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.